Longeveron(LGVN) - 2023 Q1 - Earnings Call Transcript

Longeveron Inc. (NASDAQ:LGVN) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Michael Okunewitch - Maxim Group James Clavijo Wa'el Hashad Since I joined the company in March, I have been very pleased with the progress we have made in advancing Lomecel-B for our suite of rare diseases and aging indications. We have ongoing trials on Hypoplastic Left Heart Syndrome or HLHS, Alzheimer's disease and recently, we dosed the first patient in our Phase 2 study evaluating, Lomecel-B for Aging-Related Frailt ...